Gastroenterology Unit, “Sapienza” University of Rome, Rome, Italy.
J Crohns Colitis. 2011 Dec;5(6):619-22. doi: 10.1016/j.crohns.2011.06.010. Epub 2011 Jul 28.
Anti-tumor necrosis factor alpha antibodies have been used with increasing frequency despite the number of reported adverse effects. Further new information is still emerging. Here we report the case of a 71-years-old patient affected by Crohn's disease and HCV-positive who developed Guillain-Barrè syndrome after four injections of fully human anti-tumor necrosis factor alpha antibodies (adalimumab). Indication for the treatment was severe clinical recurrence of Crohn's disease following intestinal resection. Guillain-Barrè syndrome was treated by intravenous immunoglobulins, and methylprednisolone and plasmapheresis were started with a progressive partial resolution of neurological symptoms. To date, Crohn's disease was maintained in clinical remission with low dose steroid therapy.
尽管报告的不良反应数量越来越多，但抗肿瘤坏死因子 α 抗体的使用频率仍在不断增加。进一步的新信息仍在不断涌现。在这里，我们报告了一例 71 岁的克罗恩病和 HCV 阳性患者的病例，该患者在接受四次完全人源抗肿瘤坏死因子 α 抗体（阿达木单抗）治疗后发生了格林-巴利综合征。治疗的指征是肠切除术后克罗恩病的严重临床复发。格林-巴利综合征采用静脉注射免疫球蛋白治疗，同时开始使用甲基强的松龙和血浆置换，神经症状逐渐部分缓解。迄今为止，克罗恩病在低剂量类固醇治疗下保持临床缓解。
